63. 特発性血小板減少性紫斑病 [臨床試験数:311,薬物数:185(DrugBank:39),標的遺伝子数:43,標的パスウェイ数:132

Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04214951
(ClinicalTrials.gov)
January 1, 202028/12/2019A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune ThrombocytopeniaA Prospective Observational Study of Switching Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune ThrombocytopeniaCorticosteroid-resistant or Relapsed ITPDrug: Eltrombopag;Drug: Recombinant human thrombopoietin (rh-TPO)Peking University People's HospitalNULLActive, not recruiting18 Years75 YearsAll100China
2ChiCTR1900027735
2020-01-012019-11-24Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP)Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP) Adult newly diagnosed immune thrombocytopeniaStudy group:Dexamethasone 40mg/d×4d, recombinant human thrombopoietin (rhTPO) 300U/Kg subcutaneous injection, once/d×14d, if PLT>100×109/L or PLT increase =50×109/L during treatment period RhTPO drug was discontinued; rhTPO and dexamethasone were replaced with prednisone 0.5mg~1mg/kg once a day, 0.2mg/kg per week, and the drug was stopped wit;Control group:Dexamethasone 40mg/d×4d, if the PLT>100×10^9/L or PLT increase =50×10^9/L during the treatment period, dexamethasone was replaced with prednisone 0.5mg~ 1mg/kg orally every day, reduce 0.2mg/kg per week, and quickly reduce the dose within 6~8 weeks.;Department of Hematology, Anhui Provincial HospitalNULLPending1880BothStudy group:30;Control group:30;Phase 4China
3NCT03771378
(ClinicalTrials.gov)
January 16, 20197/12/2018Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled TrialPrimary Immune ThrombocytopeniaDrug: rhTPO;Drug: eltrombopagWuhan Union Hospital, ChinaThe First Affiliated Hospital of Nanchang University;The Third Xiangya Hospital of Central South University;The First People's Hospital of Yuhang District;Xiangyang Central HospitalRecruiting18 Years75 YearsAll96Phase 4China
4NCT02139501
(ClinicalTrials.gov)
May 201413/5/2014An Investigation of rhTPO With Different Frequencies in the Management of ITPA Randomized Study to Evaluate the Efficacy and Safety of Different Doses and Frequencies of Recombinant Human Thrombopoietin (rhTPO) in the Management of Primary Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaDrug: Recombinant Human Thrombopoietin (rhTPO)Shandong UniversityThe First Affiliated Hospital of Dalian Medical University;Shandong Provincial HospitalCompleted18 Years60 YearsBoth48Phase 3China
5NCT01734044
(ClinicalTrials.gov)
July 201221/11/2012rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITPA Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: recombinant human thrombopoietin (rhTPO); dexamethasone;Drug: DexamethasoneShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;China Medical University, China;Zhejiang Provincial Hospital of TCMCompleted18 Years75 YearsBoth158Phase 3China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01734057
(ClinicalTrials.gov)
July 201221/11/2012Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: recombinant human thrombopoietin (rhTPO); rituximab;Drug: DexamethasoneShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;China Medical University, China;Zhejiang Provincial Hospital of TCMWithdrawn18 Years75 YearsBoth0Phase 3China
7NCT01525836
(ClinicalTrials.gov)
May 201131/1/2012rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITPRecombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.Purpura;Idiopathic Thrombocytopenic PurpuraDrug: rituximab; recombinant human thrombopoietin (rhTPO);Drug: RituximabShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;The First Affiliated Hospital of Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;First Hospital of China Medical UniversityCompleted18 Years72 YearsBoth123Phase 3China
8NCT01805648
(ClinicalTrials.gov)
February 201122/2/2013Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITPA Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune ThrombocytopeniaThrombocytopenia;Immune Thrombocytopenia;Idiopathic Thrombocytopenic PurpuraDrug: rhTPOPeking Union Medical CollegeShenyang Sunshine Pharmaceutical Co., LTD.Recruiting14 Years70 YearsBoth120Phase 3China
9NCT01506414
(ClinicalTrials.gov)
June 200916/11/2011Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)A Multicentre Investigation of Recombinant Human Thrombopoietin (Rh-TPO) Combine With Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: rhTPO in combination with RituximabMing HouPeking Union Medical College Hospital;Chinese Academy of Medical Sciences;First Affiliated Hospital, Sun Yat-Sen University;West China Hospital;Shandong Provincial Hospital;Wuhan Union Hospital, China;Zhejiang UniversityCompleted16 Years75 YearsBoth91Phase 3China